Engineering an Antibiotic to Fight Cancer: Optimization of the Novobiocin Scaffold to Produce Anti-proliferative Agents
作者:Huiping Zhao、Alison C. Donnelly、Bhaskar R. Kusuma、Gary E. L. Brandt、Douglas Brown、Roger A. Rajewski、George Vielhauer、Jeffrey Holzbeierlein、Mark S. Cohen、Brian S. J. Blagg
DOI:10.1021/jm200148p
日期:2011.6.9
Development of the DNA gyrase inhibitor, novobiocin, into a selective Hsp90 inhibitor was accomplished through structural modifications to the amide side chain, coumarin ring, and sugar moiety. These species exhibit ∼700-fold improved anti-proliferative activity versus the natural product as evaluated by cellular efficacies against breast, colon, prostate, lung, and other cancer cell lines. Utilization
通过对酰胺侧链、香豆素环和糖部分的结构修饰,将 DNA 促旋酶抑制剂新生霉素开发为选择性 Hsp90 抑制剂。与天然产物相比,这些物种的抗增殖活性提高了约 700 倍,正如通过对乳腺癌、结肠癌、前列腺癌、肺癌和其他癌细胞系的细胞功效所评估的那样。利用为三个新生霉素合成子建立的结构-活性关系产生了优化的支架,其表现出针对一组癌细胞系的中纳摩尔活性,并作为通过 Hsp90 抑制表现出其活性的先导化合物。